Table 2.

All Studies Using CNS-Derived Myelinating Cells That Met the Latter Inclusion Criteria.

Cell type:	OPCs	NRPs	adult NSPCs	embryonic NSPCs	embryonic GRPs	ESCs	iPS-NSCs
Study:	Bambakidis et al., 2004 Sun et al., 2014 Cao et al., 2010	Setoguchi et al., 2004	Hawryluk et al., 2014 Hofstetter et al., 2005 Karimi-Abdolrezaee et al., 2010 Mothe et al., 2013	Hu et al., 2012 Lu et al., 2010 Yasuda et al., 2011	Cao et al., 2005 Hu et al., 2013	McDonald et al.,1999	Salewski et al., 2015
Genetic / Drug Treatment:	Shh TROY inhibition CNTF	Noggin	minocycline+ cyclosporine, Neurogenin-2, ChABC, HAMC- rPDGF	Olig2/MBP activated T cells, cyclosporin A, No treatment	D15A, Schwann cell co- transplant	No treatment	No treatment

Studies that met inclusion criteria were grouped into 7 broad categories of cell types used for transplantation. Relevant genetic or pharmacologic additions are identified within each study.

Abbreviations: ChABC=Chondroitinase ABC, CNTF=Ciliary Neurotrophic Factor, ESC=Embryonic Stem Cells, GRP=Glial Restricted Precursor Cells, HAMC-rPDGF=Hyaluronan And Methyl Cellulose covalently modified with recombinant rat Platelet-Derived Growth Factor-A, iPS-NSC=induced Pluripotent Stem derived-Neural Stem Cells, NPC=Neural Precursor Cells, NRP=Neural Restricted Precursor cells, NSPC=Neural Stem Progenitor Cells, OPC=Oligodendrocyte Precursor Cells, Shh=Sonic hedgehog.